We’re Hopeful That Solasia Pharma K.K (TSE:4597) Will Use Its Cash Wisely

Even when a business is losing money, it’s possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So, the natural question for Solasia Pharma K.K (TSE:4597) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let’s start with an examination of the business’ cash, relative to its cash burn.

Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

How Long Is Solasia Pharma K.K’s Cash Runway?

A company’s cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at December 2025, Solasia Pharma K.K had cash of JP¥1.4b and no debt. In the last year, its cash burn was JP¥847m. That means it had a cash runway of around 20 months as of December 2025. While that cash runway isn’t too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time.

See our latest analysis for Solasia Pharma K.K

How Well Is Solasia Pharma K.K Growing?

Solasia Pharma K.K reduced its cash burn by 18% during the last year, which points to some degree of discipline. And considering that its operating revenue gained 36% during that period, that’s great to see. It seems to be growing nicely. Of course, we’ve only taken a quick look at the stock’s growth metrics, here. This graph of historic revenue growth shows how Solasia Pharma K.K is building its business over time.

How Hard Would It Be For Solasia Pharma K.K To Raise More Cash For Growth?

Solasia Pharma K.K seems to be in a fairly good position, in terms of cash burn, but we still think it’s worthwhile considering how easily it could raise more money if it wanted to. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. We can compare a company’s cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year’s operations.

Since it has a market capitalisation of JP¥10b, Solasia Pharma K.K’s JP¥847m in cash burn equates to about 8.2% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year’s growth by issuing some new shares to investors, or even by taking out a loan.

Is Solasia Pharma K.K’s Cash Burn A Worry?

Solasia Pharma K.K appears to be in pretty good health when it comes to its cash burn situation. Not only was its cash burn relative to its market cap quite good, but its revenue growth was a real positive. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don’t think they should be worried. On another note, Solasia Pharma K.K has 4 warning signs (and 1 which is a bit concerning) we think you should know about.

Of course Solasia Pharma K.K may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.